Best Neurology Companies in South Korea
The 99 best Neurology companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: D&D Pharmatech.
South Korea's neurology sector is moving faster than the headlines suggest, and this page ranks the best Neurology companies in South Korea by disclosed equity funding and recent funding momentum across 99 tracked players. Total disclosed capital sits at $487M, which sounds modest until you see how concentrated it is. D&D Pharmatech alone accounts for $205M of that, nearly 42% of the pool. Illimis Therapeutics follows at $57M, then Shaperon at $23M. No unicorns yet, but the funding curve is real. Globally, the neurology market is valued at roughly $112.5B in 2025 and forecast to reach $180.2B by 2032 at a 6.9% CAGR, driven by aging demographics and accelerating work in neuroimaging and genetic research.
The hot themes right now aren't the old blockbuster bets. Cognitive aging, post-concussion syndrome, and chronic traumatic encephalopathy are pulling research attention, and I'd flag that stress-induced neuroinflammation is quietly becoming a framework that connects several of these threads. Coverage is flat overall, which means you're looking at a space where a handful of well-capitalized companies can shape the narrative. Korea Investment Holdings and Company K Partners are the most active backers here. So if you're mapping where South Korean neurology capital actually concentrates, this directory is where to start.
- biospace.com
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | D&D Pharmatech Developer of GLP-1-based therapeutics for metabolic disease treatment 42Patents top 19%Funding top 23%Innovation top 28%Moat top 32% All 9 signals ▾Patentstop 19% Fundingtop 23% Innovationtop 28% Moattop 32% Talentbottom 49% Globalbottom 42% Marketbottom 39% Fin. healthbottom 39% Techbottom 31% Patents: 92 patents matched (strict assignee match) · 62 filings since 2022 vs 27 in 2017-21 Funding: Raised $205M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $205M | 12 mo ago | Public | Seulki Lee Founder | 2014 | PHPGSAPApache HTTP Server+9 | 92 patents Peptide bioconjugates with biotin/fatty acid for oral drug delivery | — |
| 2 | Illimis Therapeutics Developer of antibody-based drugs to treat neurological conditions 35Funding top 28%Moat top 31%Patents top 38%Innovation top 45% All 8 signals ▾Fundingtop 28% Moattop 31% Patentstop 38% Innovationtop 45% Talentbottom 49% Globalbottom 40% Marketbottom 39% Techbottom 30% Funding: Raised $57.4M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $57M | 11 mo ago | Series B | Sanghoon Park Co-Founder & Ceo | 2021 | PHPApache HTTP ServerCloudflare+11 | 24 patents Therapeutic biologics targeting TAM receptors and ErbB4 for immune and neurodegenerative diseases | — |
| 3 | BIORCHESTRA Developer of RNA based medicines for treating neurodegnerative disease | $45M | 51 mo ago | Series C | JH Branden Founder & CEO | 2016 | — | 151 patents Therapeutic miRNA inhibition and micellar nanoparticle drug delivery platforms | — |
| 4 | Aston Sci. Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases | $40M | 54 mo ago | Series C | — | 2018 | — | — | — |
| 5 | Astrogen Provider of drugs for neurological diseases | $24M | 52 mo ago | Series B | Hwang Soo-kyung CEO | 2017 | PHPYouTubeNginx+7 | 76 patents Patents concentrated in health & consumer products | — |
| 6 | Shaperon Developer of therapies for multiple diseases 24Patents top 20%Innovation top 24%Funding top 29%Moat top 35% All 10 signals ▾Patentstop 20% Innovationtop 24% Fundingtop 29% Moattop 35% Newstop 39% Talentbottom 49% Globalbottom 40% Marketbottom 30% Fin. healthbottom 18% Techbottom 16% Patents: 116 patents matched (strict assignee match) · 105 filings since 2022 vs 9 in 2017-21 Innovation: 116 patents (top 24% of patent-holders) · 105 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 24/100 | $23M | 2 mo ago | Public | Seung Seong Founder & CEO | 2008 | PHPUNIXOpenSSL+7 | 116 patents Therapeutic formulations of taurodeoxycholic acid and bispecific antibodies for inflammatory and respiratory diseases | — |
| 7 | 1ST Bio Developer of therapies for treating neurodegenerative and immuno-oncology diseases 53Funding top 28%Talent top 28%Market bottom 46%Global bottom 37% All 4 signals ▾Fundingtop 28% Talenttop 28% Marketbottom 46% Globalbottom 37% Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $22M | 4 mo ago | Series D | — | 2016 | — | — | — |
| 8 | NeuracleGenetics Developing gene therapies using adeno associated virus technology to treat various diseases 42Funding top 33%Market top 50%Talent bottom 49%Global bottom 36% All 4 signals ▾Fundingtop 33% Markettop 50% Talentbottom 49% Globalbottom 36% Funding: Raised $18.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Market: 30 employees (top 50% of Life Sciences) rank vs industry peers · Fliar Intelligence Index 42/100 | $19M | 9 mo ago | Series C | Kim Jong-muk CEO | 2018 | — | — | — |
| 9 | NOVOREX Developer of drugs for the treatment of cancer and central nervous diseases 32Funding top 33%AI top 45%Moat top 45%Patents top 50% All 8 signals ▾Fundingtop 33% AItop 45% Moattop 45% Patentstop 50% Talentbottom 45% Innovationbottom 38% Globalbottom 36% Marketbottom 34% Funding: Raised $15.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 32/100 | $15M | 2 mo ago | Series B | Woosung Son CEO | 2020 | — | 4 patents Small‑molecule inhibitors of LRRK2 kinase and YEATS epigenetic reader domains | — |
| 10 | Amyloid Solution Provider of therapeutics solution for treating Alzheimer’s disease | $13M | 86 mo ago | Series A | Jintae Chang CEO | 2017 | — | 46 patents Glycine transporter modulators and amyloid‑beta detection compounds for neurodegenerative disease therapy | — |
| 11 | NewLacel Genetics Developer of adeno-associated virus gene therapy to treat neurodegenerative diseases | $9M | 91 mo ago | Series A | — | 2018 | — | — | — |
| 12 | S&E bio Developer of cell therapies for neurological disorders | $7M | 41 mo ago | Series A | Oh Bang CEO | 2019 | — | 647 patents Biomedical polymers and devices for tissue regeneration, wound care, and orthopedic fixation | — |
| 13 | Ybrain Developer of electronic therapeutics and related diagnostic and monitoring technologies | $4M | 129 mo ago | Series B | Kiwon Lee CEO and CTO | 2013 | ImwebSentryFroala Editor+26 | 19 patents Patents concentrated in health & consumer products | — |
| 14 | EPD Biotherapeutics Developer of targeted protein-degrading therapeutics for cancer and neurological disorders | $3M | 47 mo ago | Seed | Seunghyun Lee Co-Founder | 2021 | — | — | — |
| 15 | Neurive Developer of electronic and digital medicines for various neurological disorders | $1M | 56 mo ago | Seed | Jae Song Founder & CEO | 2018 | — | 75 patents Wearable vagus nerve electrical stimulation devices for therapeutic neuromodulation | — |
Top 12 Neurology companies in South Korea
#1
Public · Seoul, Seoul · founded 2008 · 48 employees$23.2Mraised▾
Shaperon is the developer of therapies for multiple diseases. The platform is mainly focusing on inflammatory diseases, dermatitis, nonotherapy for cancer and developing multi-targeting stable protein structure. The platform also has multiple pipeline products include Nugel for atopic dermatitis indication are in phase two clinical trials, Nusepin for sepsis indication is in phase one clinical trials, and NuCerin for Alzheimer's indication is in preclinical stage among others.
- Apr 2026Post IPO$5.8M
- Nov 2025Post IPO$17.4M
#2
Series B · Seongnam-si, Gyeonggi-do · founded 2020 · 20 employees$15Mraised▾
Developer of drugs for the treatment of cancer and central nervous diseases. The company develops GPCR-targeted small-molecule drugs using artificial intelligence to treat neurological disorders, cognitive function, and cancer.
- Apr 2026Series B$15M
#3
Public · Seongnam-si, Gyeonggi-do · founded 2014 · 16 employees$204.7Mraised▾
Developer of GLP-1-based therapeutics for metabolic disease treatment. It focuses on building on a robust foundation of proprietary peptide research and strategic collaborations. D&D Pharmatech is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The global biotech company’s umbrella structure comprises three U.S. subsidiaries, including Neuraly Inc, its clinical research arm responsible for conducting clinical trials for the company’s pipeline, including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).
- Jun 2025Post IPO$10.8M
- Oct 2021Series C$51M
- Feb 2020Grant (prize money)—
- Aug 2019Series B$137.1M
#4
Series D · Seongnam-si, Gyeonggi-do · founded 2016 · 34 employees$22Mraised▾
1ST Bio is developing therapies for treating neurodegenerative and immuno-oncological diseases. The lead candidate of the company, 1ST 102 is a tyrosine kinase enzyme inhibitor. It's in the preclinical phase which is used for treating Parkinson's Disease. Other candidates like 1ST-101 and 1ST-103 are in the discovery stage.
- Jan 2026Series D$22M
#5
Series B · Seoul, Seoul · founded 2021 · 26 employees$57.4Mraised▾
Developer of antibody-based drugs to treat neurological conditions. The company is developing a chimeric fusion protein platform to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor.
- Jul 2025Series B$42M
- Apr 2023Series A$15.4M
- 2022Seed—
#6
Series C · Seoul, Seoul · founded 2018 · 30 employees$18.8Mraised▾
Developing gene therapies using adeno associated virus technology to treat various diseases. It is focused on treating genetic disorders and has developed several pipeline products, including NG101, which is currently in a Phase 1/2a clinical trial for the treatment of patients with a rare genetic disorder. It is also engaged in developing additional gene therapy candidates targeting various neurodegenerative disorders and rare diseases.
- Sep 2025Series C$18.8M
#7
Series C · Yuseong District, Hoseo · founded 2016 · 85 employees$45Mraised▾
Biorchestra develops RNA-based medicines for treating neurodegenerative diseases. The company is developing an RNA sequence and RNA delivery technology that delivers mRNA or microRNA regulators to the cytoplasm. The pipelined products are for Alzheimer's and amyotrophic lateral sclerosis.
- Feb 2022Series C$45M
#8
Series C · Seoul, Seoul · founded 2018 · 24 employees$40Mraised▾
Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases. The company's flagship product AST-021p that is an HSP90 peptide vaccine helps in the treatment of cancer. It has also developed AST-05X that is a GCN2 inhibitor that helps in treating cancer metabolism. Other products include AST-06X for CNS disorders, AST-301, AST-023 for cancer treatment, and more.
- Dec 2021Series C$22.7M
#9
Series B · Daegu, Daegu · founded 2017 · 38 employees$23.7Mraised▾
Provider of drugs for neurological diseases. The company uses the technology to activation of intracellular glutathione development to regeneration the damage of nerve cells through the regulation of mitochondrial function and regenerative phagocytic M2 type differentiation of microglia. The drug candidates are AST-001 (Autism), AST-002 (Traumatic brain injury and cerebrovascular disease), AST-009 (degenerative brain diseases), AST-011 (Alzheimer's disease), and AST-025 (Cerebral infarction).
- Jan 2022Series B$7.5M
- Dec 2020Series B$11.9M
- Nov 2019Series A$4.2M
#10
Series A · Seoul, Seoul · founded 2019$7.3Mraised▾
Developer of cell therapies for neurological disorders. The company is developing mesenchymal stem cell-derived extracellular vesicles therapeutics for the treatment of acute stroke, moyamoya disease, chronic stroke, dementia, cognitive disorder, and others.
- Dec 2022Series A$7.3M
#11
Series A · Seongnam-si, Gyeonggi-do · founded 2017 · 25 employees$12.8Mraised▾
AMYLOIDSOLUTION provides therapeutics solution for treating Alzheimer’s disease. The company is in the pre-clinical stage for the development of its candidate amloid-B/Tau accumulator and BBB penetration technology targeting glial dysfunctioning.
- Mar 2019Series A$12.8M
#12
Seed · Seoul, Seoul · founded 2021 · 2 employees$3.4Mraised▾
Developer of targeted protein-degrading therapeutics for cancer and neurological disorders. It offers engineered protein degraders based on bioPROTAC technology that selectively bind to the target protein to be degraded.
- Jun 2022Seed$3.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.